scholarly journals Advances in recent patent and clinical trial drug development for Alzheimer’s disease

2014 ◽  
Vol 3 (4) ◽  
pp. 429-447 ◽  
Author(s):  
Haibin Liu ◽  
Lirong Wang ◽  
Weiwei Su ◽  
Xiang-Qun Xie
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Drug Development ◽  
Trial Drug

Old Drugs with New Tricks; Paradigm in Drug Development Pipeline for Alzheimer’s Disease

2020 ◽  
Vol 20 ◽  
Author(s):  
Tanay Dalvi ◽  
Bhaskar Dewangan ◽  
Rudradip Das ◽  
Jyoti Rani ◽  
Suchita Dattatray Shinde ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Molecular Targets ◽  
Drug Repurposing ◽  
Phase Iii ◽  
Complex Nature ◽  
New Drug ◽  
Development Pipeline ◽  
Old Drugs

: The most common reason behind dementia is Alzheimer’s disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.

P2-027: TARGET ENGAGEMENT IN A PHASE II CLINICAL TRIAL OF AAV2-NGF GENE THERAPY FOR ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_12) ◽  
pp. P677-P677
Author(s):  
Michael J. Castle ◽  
Fernando Calvo Baltanas ◽  
Imre Kovacs ◽  
Alan H. Nagahara ◽  
Krystof S. Bankiewicz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Gene Therapy ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Target Engagement ◽  
Ngf Gene

P4-045: Longitudinal ADC changes in Alzheimer's disease in a multi-center clinical trial setting

2011 ◽  
Vol 7 ◽  
pp. S713-S713
Author(s):  
Luc Bracoud ◽  
Angelika Caputo ◽  
Chahin Pachai ◽  
Boubakeur Belaroussi ◽  
Ana Graf ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Clinical Trial Setting ◽  
Trial Setting

scholarly journals A clinical trial to validate event‐related potential markers of Alzheimer's disease in outpatient settings

2015 ◽  
Vol 1 (4) ◽  
pp. 387-394 ◽  
Author(s):  
Marco Cecchi ◽  
Dennis K. Moore ◽  
Carl H. Sadowsky ◽  
Paul R. Solomon ◽  
P. Murali Doraiswamy ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Event Related Potential ◽  
Outpatient Settings

Comparing the efficacy and safety ofCrocus sativusL. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial

2014 ◽  
Vol 29 (4) ◽  
pp. 351-359 ◽  
Author(s):  
Mehdi Farokhnia ◽  
Mehdi Shafiee Sabet ◽  
Negar Iranpour ◽  
Amirhossein Gougol ◽  
Habibeh Yekehtaz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Efficacy And Safety ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document